17 completed. 17 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 17 | Completed 17 |
| Phase 2 | 2 | Completed 2 |
Follow Pleural Diseases: new trials by email Literature Review of Pleural Diseases trials Research Report on Pleural Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma RSO-021 - Malignant Pleural Effusion, Malignant Pleural Mesothelioma | Phase 1 / Phase 2 | Completed | RS Oncology LLC | 50 | 2022-03-31 | 2026-07-24 |
| Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery Light Dosimetry for Intranoperative Therapy, Photodynamic Therapy, Porfimer Sodium - Malignant Mesothelioma, Non-Small Cell Lung Carcinoma | Phase 1 | Completed | Roswell Park Cancer Institute | 9 | 2021-09-17 | 2026-03-27 |
| A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion SCB-313 - Malignant Pleural Effusion | Phase 1 | Completed | Sichuan Clover Biopharmaceuticals, Inc. | 14 | 2020-01-08 | 2022-05-06 |
| Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions SCB-313 - Malignant Pleural Effusions | Phase 1 | Completed | Clover Biopharmaceuticals AUS Pty | 5 | 2019-11-20 | 2022-02-02 |
| FLOTOR Pilot Study Indocyanine Green - Chylothorax, Esophageal Cancer | Phase 1 / Phase 2 | Completed | Oxford University Hospitals NHS Trust | 21 | 2017-12-20 | 2018-11-19 |
| Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Dasatinib - 1A, Afatinib - 1A, Dasatinib - 1B - Lung Cancer, Non-small Cell Lung Cancer (NSCLC) | Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 25 | 2013-12-31 | 2020-11-27 |
| Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion AdV-tk + valacyclovir - Malignant Pleural Effusion, Lung Cancer | Phase 1 | Completed | Candel Therapeutics, Inc. | 19 | 2013-10-01 | 2023-08-25 |
| Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma GL-ONC1 - Lung Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 18 | 2013-01-01 | 2024-10-26 |
| Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Erlotinib plus Romidepsin (8 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2), Erlotinib plus Romidepsin (10 mg/m^2) + Antiemetic prophylaxis - Lung Cancer, Metastatic Cancer | Phase 1 | Completed | University of Texas Southwestern Medical Center | 17 | 2009-09-01 | 2021-01-20 |
| BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC) BAY 43-9006, Paclitaxel, Carboplatin - Lung Cancer | Phase 1 | Completed | M.D. Anderson Cancer Center | 23 | 2006-05-01 | 2016-02-10 |
| Gene Therapy for Pleural Malignancies Adenoviral-mediated Interferon-beta, SCH 721015 - Pleural Mesothelioma, Metastatic Pleural Effusions | Phase 1 | Completed | University of Pennsylvania | 17 | 2006-03-01 | 2020-03-18 |
| Surgery and Intrapleural Docetaxel in Treating Patients With Malignant Pleural Effusion docetaxel, therapeutic thoracoscopy - Metastatic Cancer | Phase 1 | Completed | University of Virginia | 24 | 2003-07-01 | 2010-03-18 |
| Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions recombinant adenovirus-hIFN-beta - Cancer | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 2003-04-01 | 2020-05-13 | |
| Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer gemcitabine hydrochloride, carboplatin, bortezomib - Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 34 | 2002-09-01 | 2013-01-23 |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer trastuzumab, tipifarnib - Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2000-06-01 | 2013-02-11 |
| Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura decitabine - Esophageal Cancer, Lung Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 1999-10-01 | 2015-04-29 | |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu recombinant interleukin-12, ABI-007/carboplatin/trastuzumab - Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 1999-08-01 | 2013-02-28 |
Pleural Effusion, Malignant (13) · Carcinoma, Non-Small-Cell Lung (9) · Lung Neoplasms (6) · Esophageal Neoplasms (5) · Mesothelioma, Malignant (5) · Breast Neoplasms (4) · Anus Neoplasms (3) · Bile Duct Neoplasms (3) · Breast Neoplasms, Male (3) · Carcinoma, Hepatocellular (3) · Carcinoma, Renal Cell (3) · Colonic Neoplasms (3) · Endometrial Neoplasms (3) · Gallbladder Neoplasms (3) · Neoplasm Metastasis (3)
Neoplasms by Site (16) · Respiratory Tract Diseases (16) · Respiratory Tract Neoplasms (15) · Thoracic Neoplasms (15) · Neoplasms (14) · Pleural Neoplasms (14) · Lung Diseases (12) · Pleural Effusion (12) · Bronchial Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (9) · Adenoma (8) · Carcinoma, Bronchogenic (8) · Lung Neoplasms (7)
Carboplatin (2) · Trastuzumab (2) · 1-phenyl-3,3-dimethyltriazene (1) · Afatinib (1) · Bevacizumab (1) · Bortezomib (1) · Dasatinib (1) · Decitabine (1) · Dihematoporphyrin Ether (1) · Docetaxel (1) · Erlotinib Hydrochloride (1) · Gemcitabine (1) · Indocyanine Green (1) · Interleukin-12 (1) · Interleukin-12 Subunit p35 (1)
National Cancer Institute (NCI) (4) · Abramson Cancer Center at Penn Medicine (1) · Candel Therapeutics, Inc. (1) · Clover Biopharmaceuticals AUS Pty (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Oxford University Hospitals NHS Trust (1) · RS Oncology LLC (1) · Roswell Park Cancer Institute (1) · Sichuan Clover Biopharmaceuticals, Inc. (1) · University of Pennsylvania (1) · University of Texas Southwestern Medical Center (1) · University of Virginia (1)
United States (13) · United Kingdom (2) · Australia (1) · China (1)
Angela Davies (1) · Anthony W. Tolcher, MD (1) · Ben Creelan, M.D. (1) · Charu Aggarwal, MD (1) · Daniel H. Sterman, M.D. (1) · Daniel H. Sterman, MD (1) · David E. Gerber, MD (1) · David R. Jones, MD (1) · David S. Schrump, MD (1) · George Blumenschein, MD (1) · James Spicer, MD (1) · Richard Gillies, MBChB (1) · Saikrishna Yendamuri (1) · Thomas Barnes, MBChB (1) · Valerie Rusch, MD (1)
PMID 20068553, PMID 29550074, PMID 34905086, PMID 36875061, PMID 42448681
N01CM17101 (1), P01CA066726 (1), U01CA076576 (1)